New research suggests that individuals who stop using blockbuster GLP-1 drugs like Wegovy and Mounjaro may regain shed pounds far faster than those who halt conventional lifestyle plans.
Research printed in a leading medical journal demonstrates that while obese individuals often shed a large proportion of their total mass while undergoing treatment, the mass comes back at an estimated rate of 0.8 kg per month upon discontinuation.
"Individuals purchasing such treatments need to be aware of the danger of rapid weight regain when the medication ends," warns expert Dr. Susan Jebb.
This pace of recovery means a return to pre-treatment weight in about 18 months.
Comparing Therapies
The research, which looked at dozens of trials involving thousands of participants, contrasted the outcomes of these new drugs with older methods.
Scientists emphasize that people who shed pounds through dieting generally experience a less rapid creep back—perhaps 0.1 kg a month—post-intervention.
Understanding the Quick Regain
Doctors propose the way of the injections accounts for the amplified regain.
GLP-1 drugs imitate a natural hormone called glucagon-like peptide-1, which moderates feelings of fullness.
"Sustained high doses of the hormone concentrations far above than the body's typical production might result in the system to produce less of its endogenous hormone, and may also lessen responsiveness to its actions," noted Dr. Adam Collins, a nutrition researcher.
"Stopping of this hormone supplement leads to appetite is no longer kept in check, making binge eating much more probable."
A Chronic Issue?
Health authorities recommend the injections for people with obesity-related medical conditions, accompanied by prescribed lifestyle changes.
Many experts say that, considering the high risk of relapse, the treatment is often long-term.
This view is echoed by drug manufacturers, who say that the results "highlight the chronic nature of excess weight," comparing it to managing conditions like diabetes.
User Accounts
Users who have stopped the jabs describe a powerful resurgence of hunger.
"It was like something activating and you're instantly ravenous," recalled a patient.
This difficulty is compounded if patients have not established sustainable dietary or behavioural changes during treatment.
Widespread Adoption
Survey data suggest that a significant number of people in the UK have tried weight-loss jabs in the past year, with demand continuing to grow.
- Adoption is higher among women compared to males.
- The middle-aged age group shows the highest usage rates.
- Many obtain the drugs through private prescriptions rather than the NHS.
In conclusion, experts stress that while GLP-1 drugs are potent agents for shedding pounds, they are not a magic solution and lasting health benefits relies on integrated behavioural changes.
